New catalyst enables targeted antibiotic redesign to beat resistant bacteria
Why it matters: This new catalyst could enable the redesign of existing antibiotics to fight drug-resistant bacterial infections.
- Superbugs are increasingly resistant to existing antibiotics, prompting the need for new treatment strategies.
- Researchers designed a new, less bulky precatalyst, HAzc-(OMe)-OMe, that can selectively oxidize secondary alcohol groups on large antibiotic molecules.
- Chemical modifications at specific sites (C11 on erythromycin A, C4'' on clarithromycin and azithromycin) prevent bacteria from inactivating the drugs, particularly against resistance mechanisms like the mph(C) gene in Staphylococcus aureus.
- The findings, published in ACS Central Science, lay the groundwork for potential new treatments for infections that no longer respond to current antibiotics.
Researchers have developed a novel azaadamantyl oxoammonium precatalyst (HAzc-(OMe)-OMe) that can chemically modify common macrolide antibiotics like erythromycin A, clarithromycin, and azithromycin. This targeted oxidation allows these drugs to bypass bacterial resistance mechanisms, offering a promising new strategy to combat superbugs that have rendered existing antibiotics ineffective.
